Osteoporosis Global Market 2016-2026: Revenue Forecasts for Antiresorptives, Anabolics and Others – our new study reveals trends, R&D progress, and predicted revenues Where is the Osteoporosis Drugs market heading? Visiongain’s report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.
Discover How to Stay Ahead Our 207 page report provides 140 charts. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Osteoporosis Drugs market.
Forecasts from 2016-2026 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. • Read full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including: – Interview with Amy Porter, CEO and Executive Director of the National Osteoporosis Foundation (NOF), US and Clare Gill, Senior Director, Marketing, Consumer and Corporate Outreach at the NOF – Interview with Paul Mitchell, founder of Synthesis Medical, an independent healthcare consultancy – Interview with Cathy Yi, Orthopaedic Physical Therapy Clinical Specialist at Pursuit Physical Therapy
Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, you find revenue forecasts to 2026 for the following submarkets: Antiresorptive drugs, Anabolic drugs and Others. These submarkets are further broken down into bisphosphonates, selective oestrogen receptor modulators, RANKL antibodies and the parathyroid hormones. Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.
Predictions of leading products’ sales – what’s possible for those Osteoporosis Drugs? How will individual osteoporosis drugs perform from 2016 to 2026 at world level? Our study forecasts revenues of these 13 brands: 1. Fosamax 2. Boniva/Bonviva 3. Actonel/Atelvia 4. Reclast/Aclasta 5. Recalbon/Bonoteo 6. Evista 7. Duavee 8. Prolia 9. Forteo 10. Odanacatib 11. Romosozumab 12. Protelos 13. Abaloparatide
Our analysis also divides the main global forecast into geographical markets.
What are the prospects in the leading regions and countries? You will discover individual revenue forecasts for 12 leading national markets from 2016-2026: • United States (US) • Japan • Germany, France, the UK, Italy and Spain (EU5 group) • Brazil, Russia, India and China (BRIC countries). • South Korea
Leading companies and the potential for market growth You can also see which companies hold the most potential: – Eli Lilly – Amgen – UCB – GSK – MSD – Allergan – Sanofi – Pfizer – Novartis – Radius Health
Research and development – assess innovation, trends and possibilities Our report discusses R&D, appraising technological, clinical and commercial possibilities. Our report forecasts prominent pipeline drugs and discusses their submarkets. 3 drugs are forecasted in this chapter with other promising drugs discussed. New submarkets are also introduced; the anti-sclerostin monoclonal antibodies and the cathepsin K inhibitors.
How the Osteoporosis Drugs Market report helps you Our new report discusses issues and events affecting the osteoporosis market. You will find quantitative and qualitative analyses on: • Revenue to 2026 for the global osteoporosis drugs market – discover the sales potential of that industry • Revenues to 2026 for the osteoporosis submarkets – find sales predictions for top treatments, seeing how they can compete and succeed • Revenue forecasts to 2026 for 13 individual osteoporosis drugs – find the current best selling osteoporosis drug and how this will change over the next 10 years • Forecasts to 2026 for 12 national markets in the Americas, Europe and Asia – discover the best countries and regions for commercial expansion • Activities of established, rising and emerging companies – hear about firms’ products, capabilities, advances and outlooks, also with industry opinions • Discussions of R&D – investigate progress in that industry, finding technological, clinical and commercial outlooks and opportunities • Analysis of what stimulates and restrains the osteoporosis market – assess challenges and strengths for those medicines, their developers, producers and sellers, helping you compete and stay ahead. • Patent expiries and how they will affect the market. • The challenges facing the market, including the entry of generics on the market. • How unmet medical needs will fuel growth in emerging markets over the next 10 years • How next generation therapies will come to dominate the market by the end of the forecast.
Our brand new survey, by our in-house UK-based analysts, provides knowledge to benefit your research, analyses, plans, decisions and proposals. It reveals information you will find nowhere else.
Our investigation provides you with definitive data, trends, opportunities and sales predictions to 2026 for the Osteoporosis drugs market.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Overview of the Osteoporosis Industry and Market 2016-2026 1.2 Why You should Read this Report 1.3 How this Study Delivers 1.4 Main Questions Answered by this Report 1.5 Who is this Investigation for? 1.6 Method of Research and Analysis 1.7 Frequently Asked Questions (FAQs) 1.8 Associated Reports 1.9 About Visiongain
2. Introduction to Osteoporosis 2.1 Osteoporosis Prevalence and Incidence in 2015 2.2 Osteoporosis: The Silent Killer 2.3 Osteoblasts are Critical in Bone Healing 2.4 Classifying Osteoporosis by Types 2.5 Classifying Osteoporosis by Treatments 2.5.1 Antiresorptive Medication 2.5.2 Anabolic Medication 2.6 Osteoporosis Risk Factors
3. Global Forecast for the Osteoporosis Market 2016-2026 3.1 The Global Osteoporosis Drug Market in 2015 3.2 The Global Osteoporosis Drug Market Forecast, 2016-2026 3.3 The Global Osteoporosis Market by Main Therapeutic Class, 2016-2026 3.3.1 The Antiresorptive Drug Submarket 3.3.1.1 Antiresorptive Drug Submarket Forecast 2016-2026 3.3.2 The Anabolic Drug Submarket 3.3.2.1 Anabolic Drug Submarket Forecast 2016-2026 3.3.3 The Others Submarket 3.3.3.1 The Others Submarket Forecast 2016-2026 3.4 Drivers and Restraints for the Global Osteoporosis Market 2016-2026
4. Individual Osteoporosis Drug Revenue Forecasts 2016-2026 4.1 The Bisphosphonates Submarket 4.1.1 The Bisphosphonates Revenue Forecast, 2016-2026 4.1.2 Merck (MSD)’s Fosamax (Alendronate) 4.1.2.1 Generic Competition for Fosamax in 2016 4.1.2.2 Fosamax Market Forecast 2016-2026 4.1.3 Roche’s Bonviva/Boniva (Ibandronate) 4.1.3.1 Boniva/Bonviva Market Forecast 2016-2026 4.1.4 Sanofi’s Actonel/Atelvia (Risedronate) 4.1.4.1 Actonel/Atelvia Market Forecast 2016-2026 4.1.5 Novartis’ Reclast/Aclasta (Zoledronate) 4.1.5.1 Reclast/Aclasta (Zoledronate) in the Leading National Markets, 2016 4.1.5.2 Generic Competition for Reclast/Aclasta (Zoledronate), 2016 4.1.5.3 Reclast/Aclasta (Zoledronate) Market Forecast 2016-2026 4.1.6 Ono Pharmaceutical’s/Astellas’ Recalbon/Bonoteo (Minodronate) 4.1.6.1 Recalbon/Bonoteo Market Forecast, 2016-2026 4.2 The SERMs Submarket 4.2.1 The SERMs Revenue Forecast, 2016-2026 4.2.2 Eli Lilly’s Evista (Raloxifene) 4.2.2.1 Generic Raloxifene Slashes Evista Profits 4.2.2.2 Evista Market Forecast 2016-2026 4.2.3 Pfizer’s Duavee 4.2.3.1 Duavee Market Forecast 2016-2026 4.3 The Global RANKL Antibody Market Forecast, 2016-2026 4.3.1 Amgen’s Prolia (Denosumab) 4.3.1.1 History of Prolia (Denosumab) 4.3.1.2 Prolia (Denosumab) Market Forecast 2016-2026 4.4 The Parathyroid Hormone Submarket 4.4.1 Parathyroid Hormone Submarket Forecast 2016-2026 4.4.2 Eli Lilly’s Forteo (Teriparatide) 4.4.3 Forteo Market Forecast 2016-2026 4.4.4 Preotact/Preos Withdrawn from the Market 4.5 The Others Submarket 4.5.1 The Others Submarket Forecast 2016-2026 4.5.2 Servier’s Protelos (Strontium Ranelate) 2016-2026 4.5.3 Protelos Market Forecast 2016-2026
5. Pipeline Drugs for the Osteoporosis Market 2016-2026 5.1 Merck (MSD)’s Odanacatib (MK 0822) 5.1.1 Odanacatib Market Forecast 2016-2026 5.2 Amgen’s Romosozumab (AMG 785) 5.2.1 Romosozumab Market Forecast 2016-2026 5.3 Blosozumab (LY2541546) 5.4 Radius Health’s Abaloparatide (BA-058) 5.4.1 Abaloparatide Market Forecast 2016-2026 5.5 ZP-PTH: Parathyroid 5.6 ZT-034: Will Need More Than Biomarkers for Approval
6. National Submarkets for the Osteoporosis Market 2016-2026 6.1 The Global Osteoporosis Market by Regional Breakdown, 2015, 2020 and 2026 6.2 The Global Osteoporosis Market Forecast by Regional Breakdown, 2015, 2020 and 2026 6.3 The US Osteoporosis Drug Market, 2015 6.3.1 The US Osteoporosis Market Forecast, 2016-2026 6.3.2 The Reimbursement System of the US 6.3.3 The US Must Improve Osteoporosis Preventation Measures 6.3.4 Drivers and Restraints for the US Osteoporosis Market, 2016-2026 6.4 The EU5 Osteoporosis Osteoporosis Market Forecasts, 2016-2026 6.4.1 The German Osteoporosis Market Forecast, 2016-2026 6.4.2 The French Osteoporosis Market Forecast, 2016-2026 6.4.3 The UK Osteoporosis Drug Market Forecast, 2016-2026 6.4.4 The Italian Osteoporosis Market Forecast, 2016-2026 6.4.5 The Spanish Osteoporosis Market Forecast, 2016-2026 6.5 The Japanese Osteoporosis Drug Market, 2015 6.5.1 The Japanese Osteoporosis Market Forecast, 2016-2026 6.5.2 Recent Trends in the Japanese Osteoporosis Market 6.6 The BRIC Countries Osteoporosis Market, 2015 6.6.1 The BRIC Countries Osteoporosis Market Forecast, 2016-2026 6.6.2 The Chinese Osteoporosis Market Forecast, 2016-2026 6.6.2.1 Drivers of Growth in the Chinese Market 6.6.3 The Indian Osteoporosis Market Forecast, 2016-2026 6.6.4 The Russian Osteoporosis Market Forecast, 2016-2026 6.6.5 The Brazilian Osteoporosis Market Forecast, 2016-2026 6.7 The South Korean Osteoporosis Market, 2016-2026 6.8 The Osteoporosis Market for the Rest of the World, 2016-2026 6.9 Additional Considerations for the National Osteoporosis Markets
7. Market Leaders for the Osteoporosis Market 2016-2026 7.1 Market Leaders in 2015 7.2 Eli Lilly 7.2.1 Eli Lilly Osteoporosis Drug Sales Forecast, 2016-2026 7.3 Amgen 7.3.1 Amgen: Reacquires All Rights for Prolia from GSK 7.3.2 Amgen Osteoporosis Drug Sales Forecast, 2016-2026 7.4 UCB 7.4.1 UCB Osteoporosis Drug Sales Forecast, 2016-2026 7.5 GSK 7.6 Merck and Co. (MSD) 7.6.1 Merck (MSD) Osteoporosis Drug Sales Forecast, 2016-2026 7.7 Allergan 7.8 Sanofi 7.9 Pfizer 7.10 Novartis 7.11 Radius Health
8. Qualitative Analysis of the Osteoporosis Market 8.1 SWOT (Strengths, Weaknesses, Opportunities and Threats) Analysis of the Osteoporosis Market, 2016-2026 8.2 STEP (Social, Technological, Economic and Political) Analysis of the Osteoporosis Market, 2016-2026
9. Research Interviews 9.1 Interview with Amy Porter, CEO and Executive Director of the National Osteoporosis Foundation (NOF), US and Clare Gill, Senior Director, Marketing, Consumer and Corporate Outreach at the NOF 9.1.1 On the Problem of Osteoporosis in Today’s Society 9.1.2 On the Work of the National Osteoporosis Foundation 9.1.3 On Drug Treatments and the Prevention of Osteoporosis 9.2 Interview with Paul Mitchell, Founder of Synthesis Medical Limited 9.2.1 On the Work of Synthesis Medical 9.2.2 On the Burden of Osteoporosis to Society 9.2.3 On Education and Policy for Osteoporosis 9.2.4 On Primary and Secondary Fractures 9.2.5 On Drug Treatments and Innovation for Osteoporosis 9.3 Interview with Cathy Yi, Orthopaedic Physical Therapy Clinical Specialist, Pursuit Physical Therapy 9.3.1 On the Therapy used at Pursuit Physical Therapy 9.3.2 On Primary and Secondary Fractures 9.3.3 On Education and Innovation for Osteoporosis
10. Conclusions 10.1 The Global Osteoporosis Market and Submarkets in 2015 10.2 The Global Osteoporosis Market and Submarkets until 2026 10.3 The National Markets for Osteoporosis in 2015 10.4 The National Markets for Osteoporosis until 2026 10.5 Leading Companies in the Osteoporosis Market 10.6 Drivers for the Osteoporosis Market 10.7 Challenges to Overcome for the Future Osteoporosis Drug Market
Associated Visiongain Reports Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form
List of Tables Table 1.1 The Global Osteoporosis Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 2.1 Mechanisms Involved in Bone Grafting Table 3.1 Treatments for Osteoporosis, by Therapeutic Classes, Drug Category and Branded Drugs, 2016 Table 3.2 The Global Osteoporosis Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026 Table 3.3 The Global Osteoporosis Drug Market: Revenue ($m) and Market Shares (%) by Therapeutic Classes, 2015, 2020 and 2026 Table 3.4 The Global Antiresorptive Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026 Table 3.5 The Global Anabolic Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026 Table 3.6 The Others Submarket Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026 Table 4.1 The Bisphosphonates Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.2 Fosamax Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.3 Boniva/Bonviva Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.4 Actonel/Atelvia Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.5 Reclast/Aclasta Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.6 Recalbon/Bonoteo Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.7 The SERMs Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.8 Evista Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.9 Duavee Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.10 Prolia Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.11 The PTH Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.12 Forteo Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.13 The Others Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 4.14 Protelos Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 5.1 Odanacatib Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 5.2 Romosozumab Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 5.3 Abaloparatide Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 6.1 The Global Osteoporosis Drug Market: Revenue ($m) by Leading Regional Markets, 2015, 2020 and 2026 Table 6.2 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2015, 2020 and 2026 Table 6.3 The Global Osteoporosis Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.4 The US Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.5 The EU5 Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.6 The Median Ages in EU5 Nations from 1960 to 2060, by Country Table 6.7 Germany Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.8 France Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.9 UK Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.10 Italy Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.11 Spain Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.12 Japan Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.13 The BRIC Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.14 China Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.15 India Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.16 Russia Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.17 Brazil Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.18 South Korea Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 6.19 RoW Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026 Table 7.1 The Eli Lilly Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 7.2 The Amgen Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 7.3 The UCB Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 7.4 The Merck (MSD) Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 7.5 The Sanofi Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 7.6 The Pfizer Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 7.7 The Novartis Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 7.8 The Radius Health Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026 Table 8.1 Strengths and Weaknesses of the Osteoporosis Market, 2016-2026 Table 8.2 Opportunities and Threats to the Osteoporosis Market, 2016-2026 Table 8.3 Social and Technological Factors of the Osteoporosis Market, 2016-2026 Table 8.4 Economic and Political Factors of the Osteoporosis Market, 2016-2026
List of Figures Figure 1.1 Global Osteoporosis Drug Market Segmentation Figure 3.1 The Global Osteoporosis Drug Market Revenue ($m) Forecast, 2016-2026 Figure 3.2 The Global Osteoporosis Drug Market AGR (%) Forecast, 2016-2026 Figure 3.3 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2015 Figure 3.4 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2020 Figure 3.5 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2026 Figure 3.6 Drivers and Restraints for the Osteoporosis Market, 2016-2026 Figure 4.1 The Bisphosphonates Revenue Forecast ($m), 2016-2026 Figure 4.2 The Bisphosphosphonates Drug Market AGR (%) Forecast, 2016-2026 Figure 4.3 Fosamax Revenue Forecast ($m), 2016-2026 Figure 4.4 Fosamax AGR (%) Forecast, 2016-2026 Figure 4.5 Boniva/Bonviva Revenue Forecast ($m), 2016-2026 Figure 4.6 Boniva/Bonviva AGR (%) Forecast, 2016-2026 Figure 4.7 Actonel/Ateliva Revenue Forecast ($m), 2016-2026 Figure 4.8 Actonel/Ateliva AGR (%) Forecast, 2016-2026 Figure 4.9 Reclast/Aclasta Revenue Forecast ($m), 2016-2026 Figure 4.10 Reclast/Aclasta AGR (%) Forecast, 2016-2026 Figure 4.11 Recalbon/Bonoteo Revenue Forecast ($m), 2016-2026 Figure 4.12 Recalbon/Bonoteo AGR (%) Forecast, 2016-2026 Figure 4.13 The SERMs Revenue Forecast ($m), 2016-2026 Figure 4.14 The SERMs AGR (%) Forecast, 2016-2026 Figure 4.15 Evista Revenue Forecast ($m), 2016-2026 Figure 4.16 Evista AGR (%) Forecast, 2016-2026 Figure 4.17 Duavee Revenue Forecast ($m), 2016-2026 Figure 4.18 Duavee AGR (%) Forecast, 2016-2026 Figure 4.19 Prolia Revenue Forecast ($m), 2016-2026 Figure 4.20 Prolia AGR (%) Forecast, 2016-2026 Figure 4.21 PTH Revenue Forecast ($m), 2016-2026 Figure 4.22 PTH AGR (%) Forecast, 2016-2026 Figure 4.23 Forteo Revenue Forecast ($m), 2016-2026 Figure 4.24 Forteo AGR (%) Forecast, 2016-2026 Figure 4.25 The Others Submarket Revenue Forecast ($m), 2016-2026 Figure 4.26 The Others Submarket AGR (%) Forecast, 2016-2026 Figure 4.27 Protelos Revenue Forecast ($m), 2016-2026 Figure 4.28 Protelos Submarket AGR (%) Forecast, 2016-2026 Figure 5.1 Odanacatib Revenue Forecast ($m), 2016-2026 Figure 5.2 Odanacatib Submarket AGR (%) Forecast, 2017-2026 Figure 5.3 Romosozumab Revenue Forecast ($m), 2016-2026 Figure 5.4 Romosozumab Submarket AGR (%) Forecast, 2017-2026 Figure 5.5 Abaloparatide Revenue Forecast ($m), 2016-2026 Figure 5.6 Abaloparatide Submarket AGR (%) Forecast, 2016-2026 Figure 6.1 The Global Osteoporosis Drug Market: Revenue ($m) by Leading Regional Markets, 2015, 2020 and 2026 Figure 6.2 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2015 Figure 6.3 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2020 Figure 6.4 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2026 Figure 6.5 The US Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.6 The US Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.7 Drivers and Restraints for the US Osteoporosis Market, 2016-2026 Figure 6.8 The EU5 Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.9 The EU5 Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.10 Germany Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.11 Germany Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.12 France Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.13 France Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.14 UK Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.15 UK Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.16 Italy Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.17 Italy Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.18 Spain Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.19 Spain Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.20 Japan Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.21 Japan Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.22 The BRIC Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.23 The BRIC Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.24 China Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.25 China Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.26 India Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.27 India Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.28 Russia Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.29 Russia Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.30 Brazil Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.31 Brazil Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.32 South Korea Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.33 South Korea Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 6.34 RoW Osteoporosis Market Revenue ($m) Forecast, 2016-2026 Figure 6.35 RoW Osteoporosis Market AGR (%) Forecast, 2016-2026 Figure 10.1 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2015 Figure 10.2 The Global Osteoporosis Market by Individual Drug Market Share (%), 2015 Figure 10.3 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2026 Figure 10.4 The Global Osteoporosis Drug Market Therapeutic Class Revenue ($m), 2015, 2020 and 2026 Figure 10.5 The Global Osteoporosis Market by Individual Drug Market Share (%), 2026 Figure 10.6 The Global Osteoporosis Market by National Market Share (%), 2015 Figure 10.7 The Global Osteoporosis Market by National Market Share (%), 2026 Figure 10.8 The Global Osteoporosis Market by Revenue ($m), 2015, 2020 and 2026
AbiogenPharma S.p.A Ablynx Actavis Ahn-Gook Pharmaceutical Ajinomoto Pharmaceuticals Co Allergan Almirall Amgen Anda, Inc Apotex Inc Asahi Kasei Astellas AstraZeneca Aurobindo Pharma Aventis Aventis Pharma Ltd Azelon Pharmaceuticals Banner Pharmacaps Banyu Barr Pharmaceuticals Bayer Celltech Chugai Pharmaceutical Co. Ltd Ciba Specialty Chemicals Ciba-Geigy Covington Venture Fund Daiichi Sankyo Dow Jones Industrial Average EffRx Pharmaceuticals Eisai Co., Ltd Eli Lilly and Company Eli Lilly Japan K.K Fermenta Biotech Glaxo Wellcome plc GlaxoSmithKline (GSK) Hoffmann-La Roche (Roche) Jiangsu Hengrui Medicine Co., Ltd LaboratoriosAtral Lacer S.A Ligand Pharmaceuticals Lighthouse Capital Partners Macleods Pharmaceuticals Medis Merck & Co (MSD) Merck Frosst Merck Sharp & Dohme Mylan Pharmaceuticals Nordic Bioscience Novartis Novartis International AG NPS Pharmaceuticals Nycomed Ono Pharma Orchid Healthcare OsteoGeneX Pfizer, Inc Procter & Gamble (P&G) Prospect Venture Partners Qingdao Chia Tai Haier Pharmaceutical Co., Ltd QS Pharma Radius Health Inc. Roche Sandoz Sanofi Pasteur Sanofi S.A Sanofi-Aventis Sanofi-Synthélabo Searle Servier SmithKline Beecham plc Sumitomo Pharma Sun Pharmaceuticals Taisho Taisho Pharmaceutical Holdings Takeda Takeda Pharmaceutical Co., Ltd Tarsa Teva Pharmaceutical Industries UCB Unigene Laboratories Warner Chilcott Wyeth Pharmaceuticals Zosano Pharma
American Society for Bone and Mineral Research (ASBMR) British National Formulary (BNF) Committee to Evaluate Drugs Derwent World Patent Index Duke University Medical Centre European Federation of Pharmaceutical Industries and Associations (EFPIA) European Medicines Agency (EMA) EMA’s Committee for Medicinal Products for Human Use (CHMP) Food and Drug Administration (FDA) German Federal Joint Committee Harvard College Health Canada HelpAge International Institute for Quality and Efficiency in Health Care (IQWiG) International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) International Osteoporosis Foundation (IOF) Japanese Ministry of Health, Labour, and Welfare Korean Federation of Industries Mayo Clinic Ministry of Civil Affairs of China National Health Service (NHS) National Institute for Health and Care Excellence (NICE) National Osteoporosis Foundation (NOF) Pedriatic Investigation Plan (PIP) Paediatric Written Request Pharmaceutical Research and Manufacturers of America (PhRMA) Plaintiffs' Steering Committee Queen Elizabeth Medical Foundation Sandwell General Hospital The Committee for Medicinal Products for Human Use (CHMP) The Committee to Evaluate Drugs (CED) Unified Health System (SUS) The United Nations US Preventive Services Task Force Washington University World Bank World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Osteoporosis Global Market 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Osteoporosis Global Market 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
